Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 4
Submit an article Journal homepage
678
Views
25
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma

Chaitra UjjaniDepartment of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USACorrespondence[email protected]
,
Pari RamziDepartment of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA
,
Edmund GehanDepartment of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Hospital, Washington, DC, USA
,
Hongkun WangDepartment of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Hospital, Washington, DC, USA
,
Yiru WangDepartment of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Hospital, Washington, DC, USA
&
Bruce D. ChesonDepartment of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA
Pages 915-920 | Received 11 Mar 2014, Accepted 05 Jun 2014, Published online: 06 Aug 2014

References

  • American Cancer Society. Cancer Facts and Figures 2014. Available from: www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index
  • Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for CLL:recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988;29:152–163.
  • Byrd J, Peterson BL, Marrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712. Blood 2003;101:6–14.
  • Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
  • Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
  • Niederle N, Megdenberg D, Balleisen L, et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol 2013;92:653–660.
  • Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378–4384.
  • Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559–3566.
  • Bakker J. Internal discovery report: Complement binding and induction of complement dependent cytotoxicity by HuMax-CD20 and HuMab-11B8. Ofatumumab Investigator's Brochure 2003; Version 8. Report No: GMB 3001-003. Brentford, UK: GlaxoSmithKline.
  • Bakker J. Internal discovery report: Efficient killing of tumor B cells by HuMax-CD20 or HuMab-11B8: antibody-dependent cell-mediated cytotoxicity and the role of whole blood components. Ofatumumab Investigator's Brochure 2003; Version 8. Report No: GMB 3001-006. Brentford, UK: GlaxoSmithKline.
  • Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002;99:3256–3262.
  • Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
  • Wierda WG, Kipps TJ, Dürig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011;117:6450–6458.
  • Hallek M, Cheson B, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
  • Cheson BD, Pfirstner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
  • Cortelezzi A, Sciumè M, Liberati AM, et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA multicenter phase II trial. Leukemia 2014;28:642–648.
  • Dolcetti R, Carbone A. Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor? Infect Agent Cancer 2010;5:22.
  • Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia:a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:3209–3216.
  • Alhafez A, Aljitawi O, Lin T, et al. Bendamustine associated with irreversible ascending paralysis. Case Rep Hematol 2013; 2013:931519.
  • Cheson B, Kroll M. Bendamustine induced neurotoxicity. Clin Adv Heme Onc 2009;11:743–746.
  • Cheson BD, Vena DA, Foss FM, et al. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994;12:2216–2228.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.